<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566514</url>
  </required_header>
  <id_info>
    <org_study_id>200604-7</org_study_id>
    <nct_id>NCT00566514</nct_id>
  </id_info>
  <brief_title>The Role of Ribose in Patients Diagnosed With Fibromyalgia</brief_title>
  <official_title>The Role of D-RIbose in Patients Diagnosed With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioenergy Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioenergy Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purose of this research study is to determine the potential benefit of D-ribose, a
      nutritional supplement (a sugar), versus a placebo (another sugar) in people with
      fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two hundred to three hundred subjects (equally distribued between placebo and D-ribose)
      between 18-78 years of age will comprise this study. The final numbers enrolled will depend
      upon obtaining approximately 100 subjects that can display a high degree of compliance to TID
      dosing with approximately equal balance between the active and placebo arms.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Protocol Under Review
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">July 2008</completion_date>
  <primary_completion_date type="Anticipated">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant reduction in symptoms of pain and fatigue</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstrate an improvement in ones quality of life</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D-ribose 5 grams TID orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dextrose 5 grams TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-ribose</intervention_name>
    <description>5 grams administered orally TID</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Corvalen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dextrose</intervention_name>
    <description>5 grams orally TID</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  previous diagnosis of fibromomyalgia by a MD

          -  Has been diagnosed with fibromyalgia and are over 18 years of age

          -  Does live in the United States

        Exclusion Criteria:

          -  does NOT have severe medication/chemical/supplement sensitivities

          -  does NOT have insulin dependent diabetes or other severe illnesses (cancer, hepatitis,
             congestive heart failure)

          -  does NOT have rheumatoid arthritis or gout

          -  previous use of ribose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Teitelbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Annapolis Center for Effective CFS/Fibromyalgia Therapies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kent Holtorf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hormone and Longevity Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioenergy Life Science, Inc.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006 Nov;12(9):857-62.</citation>
    <PMID>17109576</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <last_update_submitted>March 10, 2008</last_update_submitted>
  <last_update_submitted_qc>March 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jacob Teitelbaum, MD</name_title>
    <organization>The Annapolis Center for Effective CFS/Fibromyalgia Therapies</organization>
  </responsible_party>
  <keyword>fibromyalgia</keyword>
  <keyword>ribose</keyword>
  <keyword>d-ribose</keyword>
  <keyword>dextrose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

